Zydus launches generic Myrbetriq

Zydus is introducing mirabegron extended-release tablets, 25 mg, which is the generic of Myrbetriq.

Zydus is among the first suppliers to launch the generic version of mirabegron extended-release tablets, 25 mg in the U.S. market and is prepared to launch mirabegron extended-release tablets, 50 mg imminently.

Mirabegron is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ, India.

[Read more: Zydus obtains FDA nod for generic Sabril]

Punit Patel, CEO Americas at Zydus, said, “As one of the first suppliers, we are pleased with the launch of generic Mirabegron which will improve access and availability of the generic product for patients in the U.S. market. This is a significant launch for us which will strengthen our growth plans in U.S. market in the current fiscal.”

Mirabegron extended-release tablets 25 mg and 50 mg had a market value of $2.42 billion, per IQVIA February 2024 data.